COPENHAGEN (Reuters) -Novo Nordisk is prepared for a full-fledged launch of oral semaglutide in the United States in 2026, the group’s head of product and portfolio strategy told Reuters on Wednesday.
(Reporting by Stine Jacobsen, editing by Terje Solsvik)
Comments